These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 32307653)

  • 1. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement.
    Ulrich H; Pillat MM
    Stem Cell Rev Rep; 2020 Jun; 16(3):434-440. PubMed ID: 32307653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
    Fantini J; Chahinian H; Yahi N
    Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in Studies on Structural and Remedial Aspects of Newly Born Coronavirus, SARS-CoV-2.
    Gupta SP
    Curr Top Med Chem; 2020; 20(26):2362-2378. PubMed ID: 32962613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells.
    Wang K; Chen W; Zhang Z; Deng Y; Lian JQ; Du P; Wei D; Zhang Y; Sun XX; Gong L; Yang X; He L; Zhang L; Yang Z; Geng JJ; Chen R; Zhang H; Wang B; Zhu YM; Nan G; Jiang JL; Li L; Wu J; Lin P; Huang W; Xie L; Zheng ZH; Zhang K; Miao JL; Cui HY; Huang M; Zhang J; Fu L; Yang XM; Zhao Z; Sun S; Gu H; Wang Z; Wang CF; Lu Y; Liu YY; Wang QY; Bian H; Zhu P; Chen ZN
    Signal Transduct Target Ther; 2020 Dec; 5(1):283. PubMed ID: 33277466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
    Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic.
    Brufsky A
    J Med Virol; 2020 Jul; 92(7):770-775. PubMed ID: 32293710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.
    Catanzaro M; Fagiani F; Racchi M; Corsini E; Govoni S; Lanni C
    Signal Transduct Target Ther; 2020 May; 5(1):84. PubMed ID: 32467561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of lethal human coronaviruses.
    Chen B; Tian EK; He B; Tian L; Han R; Wang S; Xiang Q; Zhang S; El Arnaout T; Cheng W
    Signal Transduct Target Ther; 2020 Jun; 5(1):89. PubMed ID: 32533062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel coronavirus SARS-CoV-2 (Covid-19) dynamics inside the human body.
    Saha A; Saha B
    Rev Med Virol; 2020 Sep; 30(5):e2140. PubMed ID: 32686248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
    Giovane RA; Rezai S; Cleland E; Henderson CE
    Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurological injuries in COVID-19 patients: direct viral invasion or a bystander injury after infection of epithelial/endothelial cells.
    Azizi SA; Azizi SA
    J Neurovirol; 2020 Oct; 26(5):631-641. PubMed ID: 32876900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor markers as an entry for SARS-CoV-2 infection?
    Xia P; Dubrovska A
    FEBS J; 2020 Sep; 287(17):3677-3680. PubMed ID: 32738184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.
    Theoharides TC
    Biofactors; 2020 May; 46(3):306-308. PubMed ID: 32339387
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!
    Nguyen AA; Habiballah SB; Platt CD; Geha RS; Chou JS; McDonald DR
    Clin Immunol; 2020 Jul; 216():108459. PubMed ID: 32418917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesenchymal Stem Cell Therapy for COVID-19: Present or Future.
    Golchin A; Seyedjafari E; Ardeshirylajimi A
    Stem Cell Rev Rep; 2020 Jun; 16(3):427-433. PubMed ID: 32281052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scientific research progress of COVID-19/SARS-CoV-2 in the first five months.
    Li H; Liu Z; Ge J
    J Cell Mol Med; 2020 Jun; 24(12):6558-6570. PubMed ID: 32320516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
    Fantini J; Chahinian H; Yahi N
    Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32862840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19: Immunology and treatment options.
    Felsenstein S; Herbert JA; McNamara PS; Hedrich CM
    Clin Immunol; 2020 Jun; 215():108448. PubMed ID: 32353634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients.
    Sawalha AH; Zhao M; Coit P; Lu Q
    Clin Immunol; 2020 Jun; 215():108410. PubMed ID: 32276140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expressions and significances of the angiotensin-converting enzyme 2 gene, the receptor of SARS-CoV-2 for COVID-19.
    Fu J; Zhou B; Zhang L; Balaji KS; Wei C; Liu X; Chen H; Peng J; Fu J
    Mol Biol Rep; 2020 Jun; 47(6):4383-4392. PubMed ID: 32410141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.